Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 401–500 of 1,676
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 54
“This inconsistency extends to niacin’s relationship with CV risk reduction as reported by both the AIM-HIGH investigators and the HPS2-THRIVE collaborative group, who both demonstrated no additional CV clinical benefit in adding niacin to statin therapy [105,106], ruling out the role of niacin treatment in diabetic dy…”
ResultBrunham, L. R., Lonn, E., & Mehta, S. R. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.017 · Cited by 60
The role of high-density lipoproteins in the regulation of angiogenesis
Tan, J. T. M., Ng, M., & Bursill, C. A. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv104 · Cited by 50
Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
Liu, Z.-M., Hu, M., Chan, P., & Tomlinson, B. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1006359 · Cited by 45
“The two large studies that examined the addition of niacin in patients already on aggressive LDL-C lowering treatment with statin with or without ezetimibe showed no benefit and identified new adverse effects of infection and bleeding in addition to the known adverse effects of niacin such as increasing glucose levels…”
BackgroundModulating cholesterol efflux capacity to improve cardiovascular disease
Brownell, N., & Rohatgi, A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000317 · Cited by 45
“A similar result was found in the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events trial, in which high-risk participants were randomized to either niacin and laropiprant or a placebo in addition to ongoing statin therapy [5].”
ResultSharif, S., van der Graaf, Y., Nathoe, H. M., de Valk, H. W., Visseren, F. L. J., Westerink, J., & on behalf of the SMART Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0155 · Cited by 48
Rosenson, R. S. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307024 · Cited by 45
Hopewell, J. C., Offer, A. R., Haynes, R., Bowman, L. J., Li, J., Chen, F., Bulbulia, R. A., Lathrop, M. G., Baigent, C., Landray, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa574 · Cited by 45
Novel therapeutics in hypertriglyceridemia
Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44
HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
Chyu, K., & Shah, P. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00187 · Cited by 47
Niacin as antidyslipidemic drug
Julius, U. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0478 · Cited by 52
Management of lipid disorders in patients living with HIV
Myerson, M. L., Malvestutto, C., & Aberg, J. A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.473 · Cited by 47
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Stoekenbroek, R. M., Kastelein, J. J., & Huijgen, R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0503-4 · Cited by 44
Cholesterol Uptake Capacity: A New Measure of HDL Functionality for Coronary Risk Assessment
Harada, A., Toh, R., Murakami, K., Kiriyama, M., Yoshikawa, K., Miwa, K., Kubo, T., Irino, Y., Mori, K., Tanaka, N. K., et al. (2017) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.022913 · Cited by 47
Rahman, K., & Fisher, E. A. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00032 · Cited by 53
“These studies include mendelian-randomization genetic (147–149), as well as HDL-C raising interventions with niacin (150, 151) or cholesteryl ester transfer protein (CETP) inhibitors (152–154).”
BackgroundEPA’s pleiotropic mechanisms of action: a narrative review
Nelson, J. R., Budoff, M. J., Wani, O. R., Le, V. T., Patel, D. K., Nelson, A., & Nemiroff, R. L. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1921491 · Cited by 49
Ip, C.-K., Jin, D.-M., Gao, J.-J., Meng, Z., Meng, J., Tan, Z., Wang, J.-F., & Geng, D.-F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.228 · Cited by 43
Lipoprotein(a): Emerging insights and therapeutics
Kaur, G., Abdelrahman, K., Berman, A. N., Biery, D. W., Shiyovich, A., Huck, D. M., Garshick, M. S., Blankstein, R., & Weber, B. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100641 · Cited by 53
“…and 40 mg of laropiprant or matching placebo, there was an absolute difference of (cid:0) 9.5 ( p = 0.006) in Lp(a) levels; however, the trial did not show any benefit in regard to cardiovascular outcomes [92] and thus niacin is not considered to be a first-line treatment strategy for high Lp(a).”
InfluentialChandra, A., Neeland, I. J., Das, S. R., Khera, A., Turer, A. T., Ayers, C. R., McGuire, D. K., & Rohatgi, A. K. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.015 · Cited by 47
Apro, J., Tietge, U. J. F., Dikkers, A., Parini, P., Angelin, B., & Rudling, M. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307385 · Cited by 50
Kim, D. S., Li, Y. K., Bell, G. A., Burt, A., Vaisar, T., Hutchins, P. M., Furlong, C. E., Otvos, J. D., Polak, J. F., Arnan, M., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002977 · Cited by 43
Plasminogen promotes cholesterol efflux by the ABCA1 pathway
Pamir, N., Hutchins, P. M., Ronsein, G. E., Hao, W., Tang, C., Das, R., Vaisar, T., Plow, E. F., Schuster, V. H., Koschinsky, M. L., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92176 · Cited by 46
Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 47
Li, X., Guan, B., Wang, Y., Tse, G., Zou, F., Waleed, K. B., Xia, Y., Wu, S., & Sun, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50924-4 · Cited by 49
Watanabe, Y., & Tatsuno, I. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1863784 · Cited by 46
Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?
Mani, P., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0521-x · Cited by 52
Dinu, M., Sofi, F., Lotti, S., Colombini, B., Mattioli, A. V., Catapano, A. L., Casula, M., Baragetti, A., Wong, N. D., Steg, P. G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae184 · Cited by 43
Sosnowska, B., Stępińska, J., Mitkowski, P. P., Bielecka-Dabrowa, A. M., Bobrowska, B., Budzianowski, J., Burchardt, P., Chlebus, K., Dobrowolski, P., Gąsior, M., et al. (2024) · Archives of Medical Science · doi:10.5114/aoms/183522 · Cited by 65
Dyslipidemia in Special Ethnic Populations
Pu, J., Romanelli, R., Zhao, B., Azar, K. M. J., Hastings, K. G., Nimbal, V., Fortmann, S. P., & Palaniappan, L. P. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.01.005 · Cited by 42
“myopathy) in the niacin–laropiprant versus placebo group wasmarkedly higher among Chinese participants than European participants.(55) To our knowledge no safety”
My Approach to the Patient With Familial Hypercholesterolemia
Safarova, M. S., & Kullo, I. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.013 · Cited by 46
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
Zekavat, S. M., Aragam, K., Emdin, C., Khera, A. V., Klarin, D., Zhao, H., & Natarajan, P. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312626 · Cited by 42
Ajala, O. N., Demler, O., Liu, Y., Farukhi, Z. M., Adelman, S. J., Collins, H. L., Ridker, P. M., Rader, D. J., Glynn, R. J., & Mora, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016507 · Cited by 44
O’Connell, T. D., Mason, R. P., Budoff, M. J., Návar, A. M., & Shearer, G. C. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa115 · Cited by 47
Mason, R. P., & Eckel, R. H. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.03.014 · Cited by 42
Introduction to Clinical Trials
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_1 · Cited by 48
Sherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P. (2022) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2022.102450 · Cited by 43
Besseling, J., Sjouke, B., & Kastelein, J. J. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.011 · Cited by 47
Vitamin paradox in obesity: Deficiency or excess?
Zhou, S., Li, D., Chen, N.-N., & Zhou, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i10.1158 · Cited by 46
The pleiotropic vasoprotective functions of high density lipoproteins (HDL)
Guilaine, B., Emily, B., Sonja, S., & Cheryl, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160103 · Cited by 41
Huang, X., Yu, Y., Li, X., Masoudi, F. A., Spertus, J. A., Yan, X., Krumholz, H. M., Jiang, L., & Li, J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025144 · Cited by 41
Donato, M., Ferri, N., Lupo, M. G., Faggin, E., & Rattazzi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218263 · Cited by 53
“Despite its established effectiveness in lowering lipid levels, treatment with extended-release niacin has failed to show any clinical benefit in patients with atherosclerosis and background statin therapy, while it increases the frequency of serious adverse effects [51,52].”
BackgroundTreatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?
Razavi, A. C., Jain, V., Grandhi, G. R., Patel, P., Karagiannis, A. D., Patel, N. H., Dhindsa, D. S., Liu, C., Desai, S., Almuwaqqat, Z., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad406 · Cited by 50
Severe hypertriglyceridemia: Existing and emerging therapies
Malick, W. A., Do, R., & Rosenson, R. S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108544 · Cited by 40
How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL
Averna, M. R., Stroes, E. S. G., Ogura, M., Postadzhiyan, A., Čerček, M., Calabrò, P., & Suppressa, P. (2017) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(17)30021-1 · Cited by 46
Rotroff, D. M., Pijut, S. S., Marvel, S. W., Jack, J. R., Havener, T. M., Pujol, A., Schlüter, A., Graf, G. A., Ginsberg, H. N., Shah, H., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.798 · Cited by 40
Shishikura, D., Kataoka, Y., Honda, S., Takata, K., Kim, S. W., Andrews, J., Psaltis, P. J., Sweeney, M., Kulikowski, E., Johansson, J., et al. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0298-8 · Cited by 39
Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL
Hui, N., Barter, P. J., Ong, K. L., & Rye, K. (2019) · Clinical Science · doi:10.1042/cs20190873 · Cited by 46
Real-world utilization of bempedoic acid in an academic preventive cardiology practice
Warden, B. A., Cardiology, B.-A., Purnell, J. Q., Duell, P. B., & Fazio, S. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.11.013 · Cited by 39
Prognostic significance of major lipids in patients with acute ischemic stroke
Τζιόμαλος, Κ., Giampatzis, V., Bouziana, S. D., Spanou, M., Kostaki, S., Papadopoulou, M., Angelopoulou, S.-M., Tsopozidi, M., Savopoulos, C. G., & Hatzitolios, A. I. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9924-9 · Cited by 42
“However, treatment with fibrates or niacin, which reduce TG and increase HDL-C levels, did not decrease the risk for ischemic stroke in randomized controlled trials (Jun et al. 2010; Landray et al. 2014).”
BackgroundReversal of coronary atherosclerosis: Role of life style and medical management
Parsons, C. E., Agasthi, P., Mookadam, F., & Arsanjani, R. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.05.002 · Cited by 46
Streja, E., Kovesdy, C. P., Streja, D. A., Moradi, H., Kalantar‐Zadeh, K., & Kashyap, M. L. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.11.033 · Cited by 39
“This bleeding has been attributed mainly to the effect of niacin on platelets.(16) Niacin in vitro affects platelet activity by a unique inhibiting effect on aggregation and by stimulating significant prostaglandin release, while major platelet receptor expression remains mostly intact.”
BackgroundLocal Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of Atherosclerosis
Wacker, B. K., Dronadula, N., Zhang, J., & Dichek, D. A. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308258 · Cited by 39
Halcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 45
Pleiotropic effects of niacin: Current possibilities for its clinical use
Zeman, M., Vecka, M., Perlík, F., Staňková, B., Hromádka, R., TVRZICKÁ, E., Širc, J., Hrib, J., & Žák, A. (2016) · Acta Pharmaceutica · doi:10.1515/acph-2016-0043 · Cited by 38
Ljungberg, J., Holmgren, A., Bergdahl, I. A., Hultdin, J., Norberg, M., Näslund, U., Johansson, B. H., & Söderberg, S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007160 · Cited by 40
Managing Dyslipidemia in Type 2 Diabetes
Nelson, A. J., Rochelau, S. K., & Nicholls, S. J. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.004 · Cited by 39
Role of the L-PGDS-PGD2-DP1 receptor axis in sleep regulation and neurologic outcomes
Ahmad, A. S., Ottallah, H., Maciel, C. B., Strickland, M. R., & Doré, S. (2019) · SLEEP · doi:10.1093/sleep/zsz073 · Cited by 44
Wang, Y., Fang, Y., Magliano, D. J., Charchar, F. J., Sobey, C. G., Drummond, G. R., & Golledge, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac124 · Cited by 39
van Capelleveen, J. C., Kastelein, J. J. P., Zwinderman, A. H., van Deventer, S. J. H., Collins, H. L., Adelman, S. J., Round, P., Ford, J., Rader, D. J., & Hovingh, G. K. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.006 · Cited by 42
Implications of reverse cholesterol transport: Recent studies
Levinson, S. S., & Wagner, S. G. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.018 · Cited by 39
Žák, A. (2015) · Medical Science Monitor · doi:10.12659/msm.893619 · Cited by 42
“Recent large randomized clinical studies – AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides) and HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) – delivered some disappointing results, leading to the conclusion that no furt…”
BackgroundMethodInfluentialKunutsor, S. K., Khan, H. M., Nyyssönen, K., & Laukkanen, J. A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.069 · Cited by 36
Tran, J. N., Kao, T. C., Caglar, T., Stockl, K. M., Spertus, J. A., Lew, H. C., Solow, B. K., & Chan, P. S. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.8.901 · Cited by 35
“Moreover, no randomized trials of a treat-to-LDL target strategy had yet been performed,(8) and data supporting additional nonstatin therapy to lower LDL levels were inconsistent.(9-12) A major impetus for the 2013 cholesterol guideline was documented undertreatment with effective statin therapy among patients with es…”
Meta-analysis of genome-wide association studies of HDL cholesterol response to statins
Postmus, I., Warren, H. R., Trompet, S., Arsenault, B. J., Avery, C. L., Bis, J. C., Chasman, D. I., de Keyser, C. E., Deshmukh, H. A., Evans, D. S., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103966 · Cited by 37
“[7] Moreover, two large clinical trials have failed to show reduction of CVD events by nicotinic acid-induced increases in HDL-C in patients with well-controlled LDL-C levels.[36, 37] Hence, whether greater geneticallymediated HDL-C increases with statin treatment confer increased protection from CVD remains unknown.”
BackgroundScolaro, B., Kim, H. S. J., & de Castro, I. A. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1235546 · Cited by 40
Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists
Yamashita, S., Ruscica, M., Macchi, C., Corsini, A., Matsuzawa, Y., & Sirtori, C. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.035 · Cited by 37
Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks
Shemesh, E., & Zafrir, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188856 · Cited by 45
Durlach, V., Bonnefont‐Rousselot, D., Boccara, F., Varret, M., Filippo, M. D., Cariou, B., Valéro, R., Charrière, S., Farnier, M., Morange, P., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.10.009 · Cited by 43
“Recommendations for the treatment of patients with high Lp(a) are summarized in Box 3.”
Laufs, U., Scharnagl, H., & März, W. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000236 · Cited by 43
HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism
Ogura, M. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.07.004 · Cited by 47
Lipoprotein(a): Its relevance to the pediatric population
McNeal, C. J. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.07.006 · Cited by 42
Multi-omics: Opportunities for research on mechanism of type 2 diabetes mellitus
Wang, S., Yong, H., & He, X. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.1070 · Cited by 46
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 47
Linden, F., Domschke, G., Erbel, C., Akhavanpoor, M., Katus, H. A., & Gleissner, C. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00455 · Cited by 43
Metrics of High-Density Lipoprotein Function and Hospital Mortality in Acute Heart Failure Patients
Potočnjak, I., Degoricija, V., Trbušić, M., Terešak, S. D., Radulović, B., Pregartner, G., Berghold, A., Tiran, B., Marsche, G., & Frank, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157507 · Cited by 37
“Furthermore, pharmacological interventions aimed at raising HDL-cholesterol levels failed to reduce cardiovascular events [3, 4].”
BackgroundRationale and strategies for formulation development of oral fixed dose combination drug products
Moon, C., & Oh, E. (2016) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-016-0286-4 · Cited by 39
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Role for Combination Therapy in Diabetic Dyslipidemia
Warraich, H. J., Wong, N. D., & Rana, J. S. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0589-5 · Cited by 41
PCSK9 in cholesterol metabolism: from bench to bedside
Reiss, A. B., Shah, N. B., Muhieddine, D., Zhen, J., Yudkevich, J., Kasselman, L. J., & DeLeon, J. R. (2018) · Clinical Science · doi:10.1042/cs20180190 · Cited by 39
Translating Evidence of HDL and Plaque Regression
Bartolo, B. A. D., Psaltis, P. J., Bursill, C. A., & Nicholls, S. J. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.307026 · Cited by 39
Korneva, V., Kuznetsova, T. Y., & Julius, U. (2021) · Biomedicines · doi:10.3390/biomedicines9091271 · Cited by 39
Hughes-Large, J. M., Pang, D., Robson, D. L., Chan, P., Toma, J., & Borradaile, N. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.090 · Cited by 39
“Despite disappointing results in recent trials of 2 g extended release niacin as an adjunct therapy to statins (AIM-HIGH [2], HPS2-THRIVE [3,4]), niacin as a monotherapy has been shown to improve vascular health in several patient populations, including those with metabolic syndrome dyslipidemia (hypertriglyceridemia,…”
ResultDysfunctional high-density lipoprotein: an updated review
Ouyang, F. W., Chiang, H., Hsu, W., Tsai, M.-H., Huang, C.-Y., Remaley, A. T., Akyol, Ö., & Chen, C. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1713387 · Cited by 45
Drug and Gene Delivery using Sonoporation for Cardiovascular Disease
Castle, J. W., & Feinstein, S. B. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22536-4_18 · Cited by 35
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 38
Dong, H., Pi, F., Ding, Z., Chen, W., Pang, S., Dong, W., & Zhang, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137533 · Cited by 35
Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
Barter, P. J., & Rye, K. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.021 · Cited by 35
Goldberg, R. B., Bittner, V., Dunbar, R. L., Fleg, J. L., Grunberger, G., Guyton, J. R., Leiter, L. A., McBride, R., Robinson, J. G., Simmons, D. L., et al. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.039 · Cited by 34
Cholesteryl ester transfer protein inhibitors: challenges and perspectives
Filippatos, T. D., Klouras, E., Barkas, F., & Elisaf, M. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1189327 · Cited by 36
Targeting ApoC-III to Reduce Coronary Disease Risk
Khetarpal, S. A., Qamar, A., Millar, J. S., & Rader, D. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0609-y · Cited by 35
Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)
Waldmann, E., & Parhofer, K. G. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.016 · Cited by 35
Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease
Gencer, B., & Mach, F. (2020) · Drugs · doi:10.1007/s40265-019-01243-5 · Cited by 36
Langsted, A., & Nordestgaard, B. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000681 · Cited by 35
Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
Kosmas, C. E., Bousvarou, M. D., Papakonstantinou, E. J., Tsamoulis, D., Koulopoulos, A., Uceta, R. E., Guzman, E., & Rallidis, L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713622 · Cited by 40
Cooper, D. L., Murrell, D. E., Roane, D. S., & Harirforoosh, S. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.024 · Cited by 37
Cardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33
“29) but had significant increases in serious adverse events related to the treatment [21].”
BackgroundRazavi, A. C., Mehta, A., Jain, V., Patel, P., Liu, C., Patel, N. H., Eisenberg, S. D., Vaccarino, V., Isiadinso, I., Sperling, L. S., et al. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01987-3 · Cited by 37
“The intentional raising of HDL-C in primary and secondary prevention with niacin [6], fibrates [7], and/or cholesteryl ester transfer protein (CETP) inhibitors [8] has not resulted in reduced ASCVD risk, while contemporary observational cohort studies have found that very-high HDL-C (≥ 80 mg/dL in…”
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.